35 results about "Valvular heart disease" patented technology

In various embodiments, provided herein are devices, systems and methods using two, three or more pigtails for precisely imaging an aortic valve complex with minimal contrast and/or for advancing an instrument, such as a wire, or device, such as a transcatheter valve, across an aortic valve. In various embodiments, these devices, systems and methods may be used to diagnose and/or treat patients with aortic stenosis, other valvular heart disease or other cardiovascular or non cardiovascular disease, facilitating precise contrast or drug or device delivery, precise pressure measurement and/or precise drainage or sampling. In some embodiments, each of the multiple pigtails of the device may be advanced independently of one another in multiple directions and at multiple lengths of deployment to optimize position.

The invention discloses a valve clamping device for treating valvular heart diseases. The valve clamping device comprises a valve leaflet hook for lifting and fixing a valve leaflet, a clamping part for clamping an object in the clamping part through the interaction force produced by closing up and extrusion, a locking device arranged outside the clamping part and capable of making the clamping part tight in clamping and not displace, and a conveying device for conveying parts to an operation position in a minimally invasive way. The valve clamping device is applied to a lesion valve leaflet,normal chordae tendineae on two sides of the lesion part are close to each other by closing up free edges of the lesion valve leaflet, and accordingly the normal closing-up level of the valve leafletis rehabilitated. The valve clamping device has the advantages of being simple in structure, capable of achieving minimally invasive implantation, easy to operate and good in clamping effect and having clamping parts detachable or adjustable, can be applied to treatment of mitral regurgitation and tricuspid regurgitation and can be also used for other minimally invasive surgeries of several lamellar structures needing clamping.

The present invention provides modular transcatheter valve replacement devices and methods of using the same to treat valvular heart diseases. Disclosed is a bottom module that contains a heart valve replacement, and a top module connected to the bottom module. The top module may be bio-absorbable, or may contain one or more severable joints that allow the top module to be removed after implantation. The removable or absorbable top portion serves to add additional length the structure to add in orientation during implantation, but is removed or absorbed to minimize the metal and other foreign material in a patient's body that could cause thrombosis or other reactions.

The invention provides a multi-protein combined biomarker, application and a heart valvular disease complicated with atrial fibrillation diagnostic kit. The multi-protein combined biomarker is composed of an apolipoprotein A1 protein antibody, an angiotensin antigen antibody, an LIM structural domain protein 7, a macrophage colony stimulating factor receptor 1, a vitronectin antibody and a prothrombin fragment F1 + 2 antibody. Modern biological technology and bioinformatics analysis find that combined application of the six proteins has the application of predicting valvular heart disease complicated with atrial fibrillation, can be applied to preparation of targeted drugs for early intervention of related diseases, and can also be applied to preparation of a heart valvular disease complicated with atrial fibrillation screening kit. According to the kit, modeling is carried out after the concentrations of the six proteins are measured, and good evaluation efficiency and potential hugeapplication value are achieved on whether atrial fibrillation happens to a patient suffering from the heart valvular disease or not.

The invention discloses a bionic modified valve material as well as a preparation method and application thereof. The preparation method comprises the following steps: A, synthesizing drug-loaded nanoparticles for loading drugs; B, preparing cell membrane vesicles; C, mixing the drug-loaded nanoparticles with cell membrane vesicles, and performing extruding for multiple times to prepare drug-loaded nanoparticles wrapped with cell membranes; and D, crosslinking the drug-loaded nanoparticles wrapped with cell membranes to the surface of a bioprosthetic valve to obtain the bionic modified valve material. The method disclosed by the invention has the advantages of simplicity in operation, mild reaction conditions and the like, and the bionic modified valve material prepared of the drug-loadednanoparticles wrapped with cell membranes, prepared by the method disclosed by the invention can be used for well solving the problems of easiness in thrombus and calcification, endothelialization difficulty and the like of an existing glutaraldehyde cross-linked valve. Besides, a strategy of combining a cell membrane bionic drug delivery system with the valve provides a new generation of treatment mode for safe and efficient treatment of valvular heart diseases.

The invention provides a novel marker for auxiliary diagnosis of a valvular heart disease and an auxiliary diagnosis product. According to the present invention, a novel biomarker PLAUR capable of being adopted as the auxiliary diagnosis of the valvular heart disease is found for the first time, the detection speed is rapid, the result can be obtained only in one workday, at the same time, the detection sensitivity/accuracy is far higher than the NT-ProBNP and the hsCRP, and the high-throughput operation can be achieved.

There is provided the use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of cardiovascular diseases, and method for the treatment thereof. The cardiovascular diseases (CVD) may comprise several diseases associated with inflammation of the heart or arteries and include coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack), atherosclerosis, stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.

The invention discloses a construction method of a drug screening system for treating senile valvular heart disease by using a single traditional Chinese medicine. The construction method specifically comprises the following steps of constructing pmirGLO-RAGE5'-UTR and pmirGLO-mut-RAGE vectors; annealing the target fragment of the gene to synthesize double-stranded DNA, performing thermal denaturation at 95 DEG C for 2 minutes, lowering the temperature by 1 DEG C every 90 seconds to 25 DEG C, standing for 30 minutes, storing at 4 DEG C, and performing cryopreservation at -20 DEG C for later use; carrying out double enzyme digestion on the pmir GLO vector by using Sac I and Xho I enzymes so as to unlink the pmir GLO vector to be linearized; carrying out DNA recovery on a double-enzyme digestion product through agarose gel electrophoresis, and connecting the linear vector with the RAGE5 '-UTR vector; connecting the mutant target fragments by the same method to construct mutant recombinant vector plasmids; transforming the two recombinant vector plasmids and the no-load plasmid into escherichia coli DH5 alpha, picking bacterial colonies, and extracting and identifying the plasmids; and culturing 293T cells, transferring the 293T cells into plasmids containing recombinant pmirGLO-RAGE5'-UTR or pmirGLO-mut-RAGE through LipofectamineTM2000, transfecting for 24 hours, detecting the transfection efficiency, and selecting stably transfected cells, thereby successfully constructing the screening system. The screening system is simple and effective, and target sites can be replaced for popularization and application.

Medium chain fatty acids or a composition comprising medium chain fatty acids for use in the prevention or treatment of cardiac enlargement, valvular heart disease and/or a condition associated with either of the foregoing in a human.

The present invention relates to a novel use of drugs and particularly discloses an application of finerenone in preparation of drugs for treatment of senile calcific valvular heart diseases. Studiesshow that finerenone is a third-generation aldosterone receptor antagonist with strong affinity for mineralocorticoids, antagonizes a series of pathological processes caused by excessive activation ofthe mineralocorticoids by aldosterone by competitively binding mineralocorticoid receptor (MR), thus regulates cell proliferation, differentiation and apoptosis, significantly improves degenerative changes of heart valve connective tissues, fibrosis, thickening and calcification, and protects cardiomyocytes. Compared with the prior art, the finerenone can reduce various indexes of senile patientswith the calcific valvular heart diseases, improves disease conditions, and improves life quality of the senile patients with the calcific valvular heart diseases.

The invention relates to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine for treating a rheumatic valvular heart disease. The traditional Chinese medicine for treating the rheumatic valvular heart disease is prepared from the following raw materials according to a weight proportion: traditional Chinese medicines such as dangshen, mangnolia officinalis, caulis spatholobi, angelica sinensis, ephedra, radix dipsaci, cloves, tuckahoe, fructus amomi, longan aril, semen cassiae, fructus piperis longi, radix ophiopogonis, polygala tenuifolia, lithargite, fruits of Chinese wolfberry, blumea balsamifera, elecampane, smoked plum, humulus scandens, cowherb seed, honey and liquorice. The medicines adopted by the traditional Chinese medicine supplement each other, and the traditional Chinese medicine is prepared according to a formula of a traditional Chinese medicine theory and a certain weight proportion, has an obvious curative effect on treating the rheumatic valvular heart disease, has the characteristics of safety, reliability, low cost, simplicity in preparation, obvious curative effect and the like, has the effects of dispelling wind, eliminating dampness, regulating qi to alleviate pain, replenishing and activating blood, tonifying spleen and stomach, nourishing heart and calming nerves and has an excellent effect on restoring valves.